Product logins

Find logins to all Clarivate products below.


Ekaterina Kotelnikova

Associate Director for Discovery and Translational Science Consulting

Ekaterina is a highly experienced professional in bioinformatics consulting, with over 20 years of expertise in bioinformatics and systems biology. She holds a Ph.D. in molecular evolution and has a background in biophysics. Throughout her career, Ekaterina has led teams in both academic and commercial settings, specializing in drug discovery, patient subpopulation selection, and precision medicine applications using multi-omics approaches, network, and pathway analysis. She has been actively involved in establishing partnerships with interdisciplinary teams and has made significant contributions to grant applications and deliveries.

Driven by her passion for translational medicine, Ekaterina co-founded a company dedicated to NGS-based cancer treatment predictions. Working closely with molecular oncologists, bioinformaticians, and systems biologists, the company focused on the application of systems biology to precision medicine, benefiting from seed investments and grants.

Ekaterina plays a crucial role in client-facing activities and business development, conducting client needs assessments, exploring market opportunities, proposing innovative solutions, and successfully overseeing project management across various therapy areas, including oncology, neuromuscular, skin, rare, and autoimmune diseases.

Latest news

News June 17, 2026
Clarivate Releases Journal Citation Reports 2026

Advancing transparency and responsible journal evaluation London, U.K. June 17 2026 — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the Journal…

Partner news June 16, 2026
U.S. News Unveils 2026-2027 Best Global Universities Rankings

Universities in more than 100 countries are evaluated in the newest edition. Washington, D.C. – June 16, 2026 – U.S. News & World Report, the global authority in education rankings…

Partner news
News June 15, 2026
Clarivate’s IPfolio Selected by Mitsubishi Fuso

Managing intellectual property more efficiently with leading data and expertise London, U.K. June 15, 2026. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi…

Related resources

Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization